1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1630
  5. Art Unit 1635
  6. Examiner Konopka

Examiner Konopka Catherine A

1635-KONOPKA-CATHERINE-A

Employment Information

Art Unit:1635 — Drug, bio-affecting and body treating compositions
Group:1630 — Stem cells and cell culture and Nucleic Acid related therapy
Classes: 435 — Chemistry: molecular biology and microbiology
514 — Drug, bio-affecting and body treating compositions
424 — Drug, bio-affecting and body treating compositions
800 — Multicellular living organisms and unmodified parts thereof and related processes
506 — Combinatorial chemistry technology: method, library, apparatus
536 — Organic compounds -- part of the class 532-570 series
Phone:(571) 272-0330
Email:catherine.konopka@uspto.gov
Location:VA 22314
Title:Pat Examnr (Biolgy)
Service:5 years
Grade:GS-13

Grant Rate and Difficulty Ranking

87
3-Year Grant rate: 39% over 123 cases
Difficulty: Very Hard
Difficulty Percentile: 87th

With Examiner Konopka, you have a 39% chance of getting an issued patent by 3 years after the first office action. Examiner Konopka is a very hard examiner and in the 87th percentile across all examiners (with 100th percentile most difficult).

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Konopka, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1635

Examiner Konopka's grant rate is higher than that of Art Unit 1635 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Konopka 2.3
Art Unit 1635 1.6

Interview Benefit

Grant Rate without Interview

Examiner Konopka has granted 37 of 102 cases without any applicant-requested interviews for a grant rate of 36%.

Grant Rate with Interview

Examiner Konopka has granted 11 of 21 cases with at least one applicant-requested interview for a grant rate of 52%.

Interview Benefit

With Examiner Konopka, conducting an interview increases your chance of getting a patent granted by 44%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
17999341 Hdr Enhancers Rejection information available with a Premium Stats subscription. See our pricing. Abandoned View
18408504 Chemically Modified Guide Rnas For Crispr/cas-Mediated Gene Correction Abandoned View
17961274 Modified Genomes And Use Thereof Abandoned View
17436208 High-Throughput Gene-Editing Technique Abandoned View
17588289 Yap1 Gene-Modified Mesenchymal Stem Cell And Preparation Method Thereof Abandoned View
17514940 Methods And Compositions For Rna-Directed Target Dna Modification And For Rna-Directed Modulation Of Transcription Abandoned View
17823076 Mir-149-3p And Method For Treating Metabolic Disease Using The Same Abandoned View
17514936 Methods And Compositions For Rna-Directed Target Dna Modification And For Rna-Directed Modulation Of Transcription Abandoned View
17593556 Genetic Risk Analysis For Post-Traumatic Stress Disorders And Behavioral Management Thereof Abandoned View
17930079 In Vitro Cleavage Of Dna Using Argonaute Patented View
18820460 Crispr-Cas Systems And Uses Thereof Patented View
18467356 Method For Producing Dna-Edited Eukaryotic Cell, And Kit Used In The Same Abandoned View
17514929 Methods And Compositions For Rna-Directed Target Dna Modification And For Rna-Directed Modulation Of Transcription Abandoned View
17294175 Crispr/cas12j Enzyme And System Patented View
18460058 Grna Stabilization In Nucleic Acid-Guided Nickase Editing Abandoned View
18219524 Biocontainment/biocontrol System And Methods Patented View
16343987 Modular Extracellular Sensor Architecture For Regulating Genes Patented View
18068061 Dna Editing Using Single-Stranded Dna Abandoned View
17481056 Targeted Active Gene Editing Agent And Methods Of Use Abandoned View
19007236 Compositions, Systems, And Methods For Regulation Of Hepatitis B Virus Through Targeted Gene Repression Patented View
16499889 Method Of Recording Multiplexed Biological Information Into A Crispr Array Using A Retron Abandoned View
18127853 Crispr-Cas Based System For Targeting Single-Stranded Sequences Abandoned View
18537662 Allosteric Conditional Guide Rnas For Cell-Selective Regulation Of Crispr/cas Patented View
17514919 Methods And Compositions For Rna-Directed Target Dna Modification And For Rna-Directed Modulation Of Transcription Abandoned View
18467297 Method For Producing Dna-Edited Eukaryotic Cell, And Kit Used In The Same Patented View
17433927 Compositions And Methods For Treating Laminopathies Patented View
17605214 Tailored Hypoimmune Nanovesicular Delivery Systems For Cancer Tumors Patented View
18114112 Administration Regime Abandoned View
17514908 Methods And Compositions For Rna-Directed Target Dna Modification And For Rna-Directed Modulation Of Transcription Abandoned View
17514883 Methods And Compositions For Rna-Directed Target Dna Modification And For Rna-Directed Modulation Of Transcription Abandoned View
18543827 Modified Nucleic Acids, Hybrid Guide Rnas, And Uses Thereof Patented View
16913299 Rna-Guided Dna Integration Using Tn7-Like Transposons Patented View
18345653 Gene Editing Abandoned View
17514893 Methods And Compositions For Rna-Directed Target Dna Modification And For Rna-Directed Modulation Of Transcription Abandoned View
19054630 Compositions, Systems, And Methods For Regulation Of Hepatitis B Virus Through Targeted Gene Repression Patented View
16482294 Methods For Increasing Efficiency Of Gene Editing In Cells Patented View
18166746 A Htp Platform For The Genetic Engineering Of Chinese Hamster Ovary Cells Abandoned View
17388321 Type V Crispr/cas Effector Proteins For Cleaving Ssdnas And Detecting Target Dnas Patented View
17744475 Compositions And Methods Of Treatment For Lytic And Lysogenic Viruses Abandoned View
18755750 Crispr-Cas13 System And Use Thereof Patented View
15335139 Nucleic Acid Enrichment Using Cas9 Abandoned View
17284660 Methods And Kits For Identifying Cancer Treatment Targets Patented View
17750116 Altering Microbial Populations & Modifying Microbiota Abandoned View
16486799 Gene Editing Therapy For Hiv Infection Via Dual Targeting Of Hiv Genome And Ccr5 Abandoned View
18406053 Combinatorial Targeted Therapy Methods Patented View
18104640 Methods And Kits For Identifying Cancer Treatment Targets Patented View
17749017 Rna-Guided Nucleic Acid Modifying Enzymes And Methods Of Use Thereof Patented View
18520878 Systems And Methods For Targeted Integration And Genome Editing And Detection Thereof Using Integrated Priming Sites Abandoned View
16865129 Compositions And Methods For Generating Diversity At Targeted Nucleic Acid Sequences Abandoned View
17931018 Rna Guided Compositions For Preventing And Treating Hepatitis B Virus Infections Abandoned View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.